Vaxcyte Corporate Presentation

28 The Pneumococcal Vaccine Landscape Vaxcyte PCV Franchise Designed to Offer Broadest Spectrum of Coverage PCV Approaches DEVELOPER VACCINE NAME SPECTRUM OF COVERAGE GSK SYNFLORIX 10-VALENT VAXNEUVANCE MERCK MERCK V116 MERCK V117 UNKNOWN PREVNAR 13 PFIZER PREVNAR 20 SK BIOSCIENCE / SANOFI-PASTEUR TBD VAX-24 VAXCYTE (SITE-SPECIFIC CONJUGATION) VAX-XP TBD 15-VALENT 13-VALENT STATUS TARGET POPULATION: INFANTS ADULTS APPROVED EX-US FDA APPROVED IN ADULTS PHASE 3 IN INFANTS 21-VALENT • PRECLINICAL 20-VALENT PRECLINICAL SOC IN INFANTS AND ADULTS FDA APPROVED IN ADULTS PHASE 3 IN INFANTS PH 1/2 IN ADULTS 24-VALENT 30 PLUS- VALENT IND-ENABLING PRECLINICAL POC (SITE-SPECIFIC CONJUGATION) Non-PCV Approaches MERCK 23-VALENT PNEUMOVAX 23 (PS ONLY) SOC IN ADULTS POST- PCV13 AFFINIVAX / ASTELLAS ASP3772 (AFFINITY-BOUND PSS TO NOVEL PNEUMO PROTEINS) 24-VALENT PHASE 1/2 IN ADULTS о SOC standard of care; PS = polysaccharides,

View entire presentation